PRJNA874573
To investigate the molecular changes in doxorubicin resistance HeLa cell line.
Our research has demonstrated combinatorial therapies, repurposing of HDAC inhibitor and chloroquine for reversing the doxorubicin induced resistance in cervical cancer cells. However, in vivo combinatorial treatment of targeting chromatin alterations and autophagy with doxorubicin will be a step forward in translating the concept of overcoming doxorubicin resistance in cervical cancer,